Tuesday, 13 October 2026European Markets

SALMAR And EUROPRIS Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(VIANEWS) - SALMAR (SALM.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Consumer Defensive sector.

Financial Asset Price Forward Dividend Yield Return on Equity
SALMAR (SALM.OL) kr672.00 5.17% 11.63%
EUROPRIS (EPR.OL) kr69.65 4.44% 33.76%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SALMAR (SALM.OL)

5.17% Forward Dividend Yield and 11.63% Return On Equity

SalMar ASA, an aquaculture company, produces and sells farmed salmon in Asia, North America, Europe, and internationally. The company operates through Fish Farming Central Norway, Fish Farming Northern Norway, Icelandic Salmon, Sales & Industry, and SalMar Aker Ocean segments. It is involved in the broodstock, harvesting, processing, and smolt production activities. In addition, the company offers fish fillets and related products. SalMar ASA was founded in 1991 and is headquartered in Kverva, Norway.

Earnings Per Share

As for profitability, SALMAR has a trailing twelve months EPS of kr13.17.

PE Ratio

SALMAR has a trailing twelve months price to earnings ratio of 51.03. Meaning, the purchaser of the share is investing kr51.03 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.63%.

Sales Growth

SALMAR's sales growth is negative 6.5% for the ongoing quarter and 2.2% for the next.

Yearly Top and Bottom Value

SALMAR's stock is valued at kr672.00 at 12:30 EST, below its 52-week high of kr717.60 and way higher than its 52-week low of kr410.50.

More news about SALMAR.

2. EUROPRIS (EPR.OL)

4.44% Forward Dividend Yield and 33.76% Return On Equity

Europris ASA operates as a discount variety retailer in Norway. It sells own brand and branded merchandise, including laundry and cleaning, pet food and accessories, storage, confectionery and snacks, candles, seasonal items, garden, and home and interior categories, as well as groceries, toys, and do it yourself (DIY) products The company also offers its products through online shopping. Europris ASA was founded in 1992 and is headquartered in Fredrikstad, Norway.

Earnings Per Share

As for profitability, EUROPRIS has a trailing twelve months EPS of kr5.49.

PE Ratio

EUROPRIS has a trailing twelve months price to earnings ratio of 12.69. Meaning, the purchaser of the share is investing kr12.69 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 33.76%.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Apr 21, 2023, the estimated forward annual dividend rate is 2.75 and the estimated forward annual dividend yield is 4.44%.

Moving Average

EUROPRIS's value is higher than its 50-day moving average of kr65.90 and higher than its 200-day moving average of kr68.39.

Revenue Growth

Year-on-year quarterly revenue growth grew by 4.3%, now sitting on 9.33B for the twelve trailing months.

Sales Growth

EUROPRIS's sales growth is 4.3% for the present quarter and 4% for the next.

More news about EUROPRIS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com